A detailed history of Mc Clarren Financial Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mc Clarren Financial Advisors, Inc. holds 1 shares of VRTX stock, worth $408. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 468 99.79%
Holding current value
$408
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$460.0 - $505.78 $214,820 - $236,199
-467 Reduced 99.79%
1 $0
Q2 2024

Jul 26, 2024

BUY
$392.81 - $485.53 $183,442 - $226,742
467 Added 46700.0%
468 $0
Q1 2024

Jul 26, 2024

SELL
$407.69 - $446.08 $170,414 - $186,461
-418 Reduced 99.76%
1 $1,000
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $170,414 - $186,461
418 Added 41800.0%
419 $1,000
Q4 2022

Jan 30, 2023

BUY
$285.76 - $321.48 $285 - $321
1 New
1 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mc Clarren Financial Advisors, Inc. Portfolio

Follow Mc Clarren Financial Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Clarren Financial Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mc Clarren Financial Advisors, Inc. with notifications on news.